SCC80TH ANNUAL SCIENTIFIC MEETING & SHOWCASE
DECEMBER 1 - 2, 2026 | JW MARRIOTT LA LIVE LOS ANGELES, CA



Addressing GLP-1-Associated Skin Changes: A Multi-Mechanistic Strategy Targeting Elasticity Loss, Dermal Integrity, and Facial Architecture

Dermalogica, LLC

www.dermalogica.com

PRODUCT/SERVICE BACKGROUND INFORMATION

The rapid adoption of GLP-1 receptor agonists for weight management has introduced a growing consumer concern: visible changes in skin quality, including loss of elasticity, increased laxity, sagging, and facial volume loss. These effects are largely associated with rapid adipose volume reduction and tissue remodeling that may outpace the skin's adaptive capacity, resulting in reduced recoil, altered mechanical support, and diminished structural resilience.

WHAT IS THE COMPANY INTRODUCING TO THE MARKET/INDUSTRY?

Dermalogica is presenting a multi-mechanistic skincare strategy designed to address visible skin changes associated with GLP-1-mediated weight loss. The approach targets three complementary needs: dermal matrix support to preserve collagen and elastin networks; improved skin recoil and firmness; and barrier/hydration balance. Existing adaptive peptide and hydration technologies provide a foundation, with future development extending toward the jawline and lower facial architecture.

HOW WILL THIS NEW PRODUCT/SERVICE IMPACT THE INDUSTRY (BENEFITS)?

This framework connects an emerging consumer need with mechanistic skin science and provides a scalable pathway for future skincare innovation. By combining immediate perceptual correction with longer-term support of skin structure, hydration, barrier function, and resilience, the strategy can help address visible laxity, sagging, and contour changes associated with rapid weight loss while guiding development of targeted, high-performance solutions across the face.